Akers Biosciences Profit Margin

Akers Biosciences (AKER) currently reports a profit margin of -3948.27% as of December 2020. That compares with -369.23% in the prior-year period — down 969.3% year over year. That is below the Healthcare sector average of 19.13%. Use the charts on this page to explore Akers Biosciences's profit margin history and peer comparisons.

Akers Biosciences's profit margin decreased from -369.23% to -3948.27% — a 969.3% year-over-year decrease (period ending December 2020). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Akers Biosciences's profit margin of -3948.27% is lower than the Healthcare sector average of 19.13%. That is roughly 20737.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Akers Biosciences's current -3948.27% should be judged against Healthcare norms (sector average: 19.13%) and against AKER's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -3948.27%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 19.13%. From there, open related valuation or income-statement pages for Akers Biosciences, and consider following AKER for alerts when major investors trade the stock.